Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Recently, I published an article describing why I believe Crispr Therapeutics ( CRSP ) is on a good track to achieve profitability by 2028 or earlier, despite the slow Casgevy rollout and the marketOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to asses ...